The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it buy, with a mean price target of $186.
Raymond James Financial
RJF · a US exchange · USD · Market cap $32.1B · 19,500 employees
Raymond James Financial, Inc., a diversified financial services company, provides private client group, capital markets, asset management, banking, and other services to individuals, corporations, and municipalities in t…
FAIL · Does not pass the screenScreen close, 2026-09-18 · not a live quote
Last reviewed 4 days ago
Screened 2026-09-18 · the tape above runs as of 09:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 164.75 against the desk's fair-value range, base estimate 199.98, over the last year.
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Raymond James Financial holds its Distribution at $164.75. Consolidating, no directional conviction, held for 51 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 51 days |
| Price at the screen | $164.75 |
| Valuation | 14.35 trailing · 11.60 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.92 |
Five Screens, Shown in Full
Does not pass. Business activity screen
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Business activity: Financials sector | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads AVOID: it trades at roughly a 21% discount to our $199.98 fair value, moderate competitive moat, 15.10% revenue growth.
Fair value range in USD, drawn from the 2026-09-18 screen. The gold marker is the market price at the same screen. A 21.4% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +14% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsBrokers Can Look Cheap Yet Still Fail Us
Picture a steady wealth manager guiding retirees through market swings while quietly tripping an ethical screen on core business lines. That is Raymond James at 168 dollars a share, with analysts clustered around a 179 target and our own fair value at 195. We pass anyway.
Revenue is growing 13 percent and the firm earns a 17 percent return on equity with a moderate moat, yet the ethical failure on business activity rules it out regardless of the 11.9 times forward earnings or 15 percent profit margin. The 16 percent margin of safety to our number changes nothing when the screen is breached.
Risk sits in the ethical breach itself plus any cyclical pressure on asset management fees when markets turn. Analysis, not advice.
| Forward P/E | 11.6xfairly priced for its growth rate |
| Trailing P/E | 14.4xreasonably valued |
| EPS, trailing | 11.48 |
| EPS, forward | 14.20 |
| Revenue growth | +15.1%steady growth |
| Profit margin | 15.1%healthy profit margins |
| Return on equity | 18.4%a solid return on shareholder capital |
| Dividend yield | 140.00% |
| Debt to equity | 0.48minimal debt: a conservative balance sheet |
| Current ratio | 2.11comfortably covers its short-term bills |
| Beta | 0.92steadier than the market |
| Short interest, float | 0.05% |
| 52-week range | 138.82 - 182.73 |
| Moat | MODERATE |
| Market cap | $32.1B |
| Employees | 19,500 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeRJF trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it buy, with a mean price target of $175.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it buy, with a mean price target of $175.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Raymond James Adds Retirement Plan Option for Small Business Owners Wealth Management · 6d ago
- 3 Market-Beating Stocks Worth Investigating StockStory · 6d ago
- Is Raymond James Financial Stock Underperforming the S&P 500? Barchart · 7d ago
- 1 Surging Stock with Solid Fundamentals and 2 Facing Headwinds StockStory · 7d ago
- Top Analyst Reports for Eli Lilly, Palo Alto Networks & Texas Instruments Zacks · 13d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-19 | ALLAIRE BELLA LOYKHTER | Officer | 29,551 | $4,206,289 | |
| 2026-02-27 | AISENBREY CHRISTOPHER S | Officer | 600 | · | |
| 2026-02-24 | EDWARDS JEFFREY N. | Director | 1,503 | · | |
| 2026-02-19 | EDWARDS JEFFREY N. | Director | 1,253 | · | |
| 2026-02-19 | MISTARZ, CECILY | Director | 1,753 | · | |
| 2026-02-19 | DEBEL MARLENE | Director | 1,253 | · | |
| 2026-02-19 | ESTY BENJAMIN C | Director | 1,303 | · | |
| 2026-02-19 | SESHADRI RAJEEV | Director | 1,303 | · | |
| 2026-02-19 | BEGOR MARK W. | Director | 1,303 | · | |
| 2026-02-19 | MCGEARY RODERICK C | Director | 1,303 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $151.04 | -0.1% | · | $999 | -0.1% |
| 2 months | $146.19 | +3.2% | · | $1,032 | +3.2% |
| 3 months | $144.04 | +4.7% | $0.54 | $1,051 | +5.1% |
| 6 months | $162.75 | -7.3% | $1.08 | $934 | -6.6% |
| 1 year | $144.94 | +4.1% | $2.08 | $1,055 | +5.5% |
| 2 years | $116.32 | +29.7% | $3.98 | $1,331 | +33.1% |
| 3 years | $91.63 | +64.6% | $5.72 | $1,709 | +70.9% |
| 5 years | $81.40 | +85.3% | $8.44 | $1,957 | +95.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever RJF does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.